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Two-hundred consecutive, single patient isolates of Enterobacter spp., Serratia spp., Citrobacter spp., and
Pseudomonas aeruginosa were evaluated for AmpC production using a variety of inducer-substrate antibiotic
combinations in a disk approximation format. The combinations examined included cefoxitin-piperacillin,
imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin. All
isolates were also screened for the presence of extended-spectrum ␤-lactamase (ESBL) activity. In total, 85.5%
of isolates were shown to be inducible for the production of AmpC by one or more inducer/substrate combinations and 11% of all isolates were stably derepressed for the expression of AmpC. Of all of the combinations,
imipenem/piperacillin-tazobactam provided the greatest sensitivity (97.1%). All combinations were 100% specific when a positive test was observed. Given this background among these organisms in our institution, it is
reasonable to develop an antibiotic reporting strategy that favors the selection of agents for therapy of these
organisms that do not serve as labile substrates of AmpC.
Antimicrobial therapy of serious infections caused by Enterobacter and Serratia species, Citrobacter freundii, and Pseudomonas aeruginosa (ESCP) can be problematic since many of these
organisms possess inducible AmpC ␤-lactamases (AmpC) that
can be upregulated by subinhibitory concentrations of certain
␤-lactam antibiotics (6, 11, 14). Further, mutations can occur in
the regulatory components of AmpC leading to a stable, hyperproduction of AmpC with concomitant high-level resistance to
many classes of ␤-lactam antibiotics (14). The ability of various
␤-lactam antibiotics to induce AmpC synthesis in ESCP organisms varies with some agents such as ampicillin, cefoxitin, and
carbapenems acting as strong inducers. Extended-spectrum
cephalosporins such as ceftazidime and cefotaxime, and ureidopenicillins do not readily induce but can serve as substrates of
AmpC (11).
Routine antimicrobial susceptibility testing using either disk
diffusion or broth microdilution can generally differentiate between strains of ESCP whose AmpC enzymes remain uninduced
or are hyperproduced based on resistance profiles versus a spectrum of ␤-lactam antibiotics. However, these methods cannot
readily predict which strains carry inducible AmpC enzymes. In
the absence of this information, reporting algorithms could be
established wherein resistance to all narrow-, expanded-, and
broad-spectrum cephalosporins, ureidopenicillins, and carboxypenicillins (the latter two with or without ␤-lactamase inhibitors) is assumed considering the potential for selection of stably derepressed or induced AmpC-producing strains during
therapy. More practically, however, it would be useful to de-

velop a simple screening assay to detect inducible AmpC that
would have sufficient sensitivity and specificity for ESCP to
allow reporting along with susceptibility results. The purpose
of the present study was twofold. The first was to evaluate the
performance of several inducer/substrate combinations in order to establish the AmpC status of ESCP. The second was to
screen a representative number of ESCP isolates from our
institution to determine whether a reporting algorithm relative
to ␤-lactam antibiotic testing was a reasonable alternative to
AmpC screening.
MATERIALS AND METHODS
Bacterial strains. For the present study, 200 consecutive single patient isolates
of Enterobacter, Serratia, and Citrobacter spp. and P. aeruginosa were collected
over a 3-month period from May through July 2005. Isolates were identified by
using either the VITEK2 colorimetric or API identification systems (bioMérieux
SA, Marcy l’Etoile, France). The collection consisted of 134 P. aeruginosa strains
and 13 Citrobacter (9 freundii, 3 koserii, and 1 amalonaticus), 13 Serratia marcescens, and 40 Enterobacter (24 cloacae and 16 aerogenes) isolates. All isolates
were either tested immediately or maintained on Trypticase soy agar slants at
room temperature for up to 48 h prior to testing.
Induction of AmpC. The induction of AmpC synthesis was based on the disk
approximation (D-test) assay as previously described (9) using cefoxitin/piperacillin (FOX/PIP) and adding several other inducer/substrate combinations for
comparison, including imipenem/cefotaxime (IMI/CTX), imipenem/ceftazidime
(IMI/CAZ), imipenem/piperacillin-tazobactam (IMI/TZP), and imipenem/
cefoxitin (IMI/FOX). In addition, comparisons were made between zone sizes
produced by a disk containing CAZ alone and one with ceftazidime and clavulanate (CAZ-CLAV) to look for evidence of extended-spectrum ␤-lactamase
(ESBL) production and/or AmpC induction by clavulanate. Inhibitory zone sizes
generated by a PIP disk and a TZP disk were compared to detect tazobactam
induction of AmpC. All disks were obtained from BBL (Becton Dickinson,
Sparks, MD) at the following potencies: TZP (100 and 10 g, respectively [100
g-10 g]), PIP (100 g), IMI (10 g), CAZ-CLAV (30 and 10 g, respectively),
CAZ (30 g), FOX (30 g), and CTX (30 g).
To perform the assay, disk diffusion susceptibility testing was performed according
to the CLSI guidelines (15). Inducer/substrate disks were place on the surface of

* Corresponding author. Mailing address: Departments of Pathology
and Immunology, Washington University School of Medicine, 660 S.
Euclid Ave., Box 8118, St. Louis, MO 63110. Phone: (314) 362-1547. Fax:
(314) 362-1461. E-mail: dunne@wustl.edu.
5945

Downloaded from http://jcm.asm.org/ on March 28, 2014 by Washington University in St. Louis

Use of Several Inducer and Substrate Antibiotic Combinations in a
Disk Approximation Assay Format To Screen for AmpC Induction
in Patient Isolates of Pseudomonas aeruginosa, Enterobacter spp.,
Citrobacter spp., and Serratia spp.

5946

DUNNE AND HARDIN

J. CLIN. MICROBIOL.
derepression of AmpC for all strains was confirmed with a disk potentiation test
(18) using 3-aminophenylboronic acid (APB; Sigma-Aldrich, St. Louis, MO) as
an inhibitor of AmpC ␤-lactamases. Strains identified as resistant to IMI were
also evaluated for metallo-␤-lactamase production using the double disk synergy
method of Arakawa et al. (2) with 2-mercaptopropionic acid as a specific inhibitor of enzyme activity.

RESULTS

Mueller-Hinton agar plates (BBL) at a distance of 25 mm on center using a template
(Fig. 1). After incubation, zones of inhibition were measured on both the induced
(adjacent to the inducer disk) and the uninduced side of the substrate disk from disk
edge to zone edge. A test was considered positive if the zone of inhibition was
reduced by ⱖ2 mm on the induced side of the substrate disk.
Quality control of the performance of the assay was accomplished with positive
(P. aeruginosa ATCC 27853) and negative (Escherichia coli 25922) control
strains. Assays performed on 5 consecutive days provided positive results for
each inducer/substrate pair except IMI/FOX with the positive control. Negative
results were obtained for each inducer/substrate combination with the E. coli
ATCC 25922 except the IMI/FOX pair where a faint blunting of the induced side
of the FOX disk was observed. It has previously been noted that this strain
produces low levels of AmpC that might contribute to this observation (3).
Neither control strain showed any zone size difference between the CAZ-CLAV
and CAZ or the PIP and TZP disks.
Study strains were considered to be noninducible if none of the substrate/
inducer combinations produced a positive test and the isolate was not stably
derepressed for AmpC. Strains were considered inducible if a positive test was
obtained with any of the inducer/substrate combinations or if the zone of inhibition produced by the CAZ-CLAV disk was ⱖ2 mm less than the zone produced
by a CAZ disk. Strains were considered to be stably derepressed if resistance was
observed to all substrate drugs and could be confirmed by inhibition of AmpC
activity without evidence of metallo-␤-lactamase production. The induction or

TABLE 1. Sensitivity of AmpC induction screening assay for each inducer/substrate combination examined and mean difference
in inhibitory zone size between the uninduced and induced side of the substrate disk for a positive test (ⱖ2 mm)a
% Sensitivity, mean difference (mm)a
Organism

Pseudomonas aeruginosa
Enterobacter spp.
Citrobacter spp.
Serratia spp.
All organisms
a
b

FOX/PIP

IMI/CTX

IMI/CAZ

IMI/TZP

IMI/FOX

40, 2.4 (2)
29.4, 2.4 (2)
30, 2.0 (0)
66.7, 3.3 (4)
39.8, 2.5 (4)

69, 5.2 (6)
85.2, 3.9 (6)
90, 4.3 (4)
100, 3.3 (3)
75.4, 4.7 (6)

100, 3.7 (5)
76.4, 3.4 (4)
90, 2.8 (2)
91.7, 2.4 (3)
94.2, 3.5 (5)

100, 4.4 (7)
94.1, 2.9 (3)
80, 2.9 (2)
91.7, 3.4 (5)
97.1, 4.0 (7)

0, NAb (NA)
2.9, 4.0 (4)
30, 4.5 (2)
8.3, 6 (4)
2.3, 3.8 (4)

The absolute range (maximum difference minus 2 mm) is shown in parentheses. The specificity of each screening combination was 100%.
NA, not applicable.
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FIG. 1. Template used for the placement of antibiotic disks on the
surface of a 140-mm Mueller-Hinton agar plate (BBL) to test for the
induction of AmpC. Inducer/substrate combination disks were placed
adjacent to one another at a distance of 25 mm on center. Disk potency
is as follows: TZP (100 g-10 g), PIP (100 g), IMI (10 g), CAZCLAV (30 g-10 g), CAZ (30 g), FOX (30 g), and CTX (30 g).

P. aeruginosa. A total of 134 strains of P. aeruginosa were
collected among the 200 total isolates included in the study. Of
these, 115 (85.8%) were shown to be inducible for AmpC by
one or more of the substrate/inducer combinations by using an
affirmative confirmation test. The sensitivity of each screening
combination was as follows: FOX/PIP, 40%; IMI/CTX, 69%;
IMI/CAZ, 100%; and IMI/TZP, 100% (Table 1). The combination of IMI/FOX was not useful for evaluating strains of P.
aeruginosa since none of the isolates produced a zone of inhibition surrounding the FOX disk. A comparison of the zone
sizes produced by CAZ and CAZ-CLAV was useful for the
detection of AmpC induction in seven strains (6.2%) and six of
these seven isolates were also resistant to IMI. Tazobactam
induced AmpC in three strains as the zone size generated by
TZP was ⱖ2 mm smaller than that produced by PIP alone. The
specificity of all substrate/inducer combinations was determined to be 100% by the APB confirmation assay. The mean
difference in inhibitory zone size between the induced and
uninduced sides of the substrate disk gave the following rank
for the AmpC induction test: IMI/CTX ⬎ IMI/TZP ⬎ IMI/
CAZ ⬎ FOX/PIP (Table 1).
Of 134 isolates of P. aeruginosa, 15 (11.2%) were stably
derepressed for the production of AmpC. Of these, six were
also resistant to IMI, which was reversed by ABP. None of the
IMI-resistant strains were shown to produce a metallo-␤-lactamase using zone expansion with 2-mercaptopropionic acid.
Only 4 of 134 strains of P. aeruginosa showed no induction of
AmpC using any of the substrate/inducer combinations. All of
these were susceptible to IMI, CTX, CAZ, PIP, and TZP, and
none demonstrated an enhanced zone of inhibition with the
addition of APB (data not shown).
Enterobacter spp. A total of 40 Enterobacter spp. (24 E. cloacae
and 16 E. aerogenes) were collected during the study period.
Twenty-two of twenty-four strains of E. cloacae and twelve of
sixteen E. aerogenes isolates (90% of the total) were shown to
be inducible for AmpC synthesis by one or more of the inducer/substrate combinations (Table 1). Of the 40 isolates, 6 (4 E.
aerogenes and 2 E. cloacae) were stably derepressed for Amp C
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CAZ. The combination of IMI/FOX was only positive for one
isolate (6-mm difference).
Cumulative results. A total of 171 of the 200 ESCP isolates
collected for the present study (85.5%) could be induced for
synthesis of AmpC based on a positive test with at least one of
the screening combinations evaluated and confirmed with the
addition of APB. The sensitivities of the various screening
combinations for all ESCP isolates were as follows: IMI/FOX,
2.3%; FOX/PIP, 39.8%; IMI/CTX, 75.4%; IMI/CAZ, 94.2%;
and IMI/TZP, 97.1%. The comparison of zones produced by
CAZ-CLAV and CAZ led to the detection of AmpC induction
in 11 isolates (6.4%), but all were determined to be positive by
two or more of the other screening assays. Tazobactam apparently caused induction of AmpC production in 4 of the 171
isolates (2.3%) but, again, each of these produced a positive
screening test with at least two of the other combinations. A
total of 22 isolates (11%) were stably derepressed for AmpC
production, whereas only 6 of 200 strains (3%) could not be
induced for AmpC production with any of the inducer/substrate combinations, including 4 of 134 (3%) P. aeruginosa, 2 of
13 Citrobacter spp. (15.4%, both C. koseri), 1 of 13 S. marcescens (7.6%), and no Enterobacter species.

DISCUSSION
The purpose of this investigation was twofold: first, to examine the status of AmpC production among ESCP from our
facility so as to better understand treatment options in the
setting of serious systemic infection and, second, to develop a
simple and sensitive screening assay to evaluate AmpC activity
in these organisms. Using several inducer/substrate combinations, we found that 85.5% of single patient ESCP isolates
collected for the present study were capable induced synthesis
of an AmpC. This finding is not unexpected since it is well
known that these genera harbor inducible AmpC enzymes
(6, 11, 14). One unusual finding was the identification of one
strain each of Citrobacter koseri and C. amalonaticus that were
positive for inducible AmpC. Although AmpC activity has
been associated with C. koseri (7), we are unaware of reports
detailing AmpC activity in C. amalonaticus. More importantly,
however, this finding serves to remind that inducible AmpC is
not monopolized by C. freundii but can be shared by other
Citrobacter species.
A total of 22 isolates (11%) were stably derepressed for
AmpC production, including 15 of 134 P. aeruginosa, 4 of 40
Enterobacter sp., and 1 of 13 C. freundii isolates, but no isolates
of S. marcescens. With respect to Enterobacter and Citrobacter
spp., the frequency of strains demonstrating stable derepression of AmpC is much less than that the 38% reported by
Pfaller et al. (17) for the same genera when they examined
bloodstream isolates for the SCOPE surveillance program.
Our numbers, however, are much smaller and reflect organisms recovered from many sources other than blood.
As a sidelight, we identified 16 isolates of IMI-resistant P.
aeruginosa. We found that 9 of these demonstrated inducible
AmpC production, while 7 isolates were stably derepressed for
AmpC production. IMI activity was potentiated in all isolates
by ABP but not with 2-mercaptopropionic acid, indicating that
IMI resistance was mediated by a combination of AmpC and
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production, and none were noninducible. AmpC expression
was confirmed for all inducible and derepressed strains using
APB. The sensitivity of each screening combination for inducible Enterobacter species was as follows: FOX/PIP, 29.4%; IMI/
CTX, 85.2%; IMI/CAZ, 76.4%; and IMI/TZP, 94.1% (Table
1). As with P. aeruginosa, the combination of IMI/FOX was not
useful (sensitivity ⫽ 2.9%) because most strains were resistant
to FOX. The rank order of screening combinations for Enterobacter species in terms of zone reduction was as follows:
IMI/CTX ⬎ IMI/CAZ ⬎ IMI/TZP ⬎ FOX/PIP for a positive
induction test (Table 1).
Five isolates of E. cloacae were shown to produce both
inducible AmpC and ESBL activity as determined by comparison of the CAZ-CLAV and CAZ disks. This finding was
confirmed according to the CLSI protocol (15, 16). The only
screening test able to detect inducible AmpC in these five
isolates was the IMI/TZP combination. Six Enterobacter isolates (4 E. aerogenes and 2 E. cloacae) were stably derepressed
for the production of AmpC and confirmed by APB inhibition.
None of the 40 Enterobacter strains was resistant to IMI, produced a metallo-␤-lactamase, or was noninducible. Comparison of the PIP and TZP zone sizes gave no indication of
tazobactam induction of AmpC in Enterobacter species.
Citrobacter spp. Thirteen Citrobacter spp. consisting of 9 C.
freundii, 3 C. koseri, and 1 C. amalonaticus isolate were among
the study isolates. AmpC induction was demonstrable for 10 of
these (8 C. freundii and 1 each C. koseri and C. amalonaticus)
with one or more inducer/substrate combinations. One isolate
of C. freundii was stably derepressed for AmpC synthesis, and
two isolates of C. koseri could not be induced. AmpC activity
was confirmed for all inducible and derepressed strains with
APB, and none of the isolates was resistant to IMI or had
evidence of metallo-␤-lactamase activity. The sensitivities of
each inducer/substrate combinations to detect AmpC induction were as follows: FOX/PIP, 30%; IMI/CTX, 90%; IMI/
CAZ, 90%; IMI/TZP, 80%; and IMI/FOX, 30% (Table 1).
One strain of C. freundii demonstrated AmpC induction by
comparison of the CAZ-CLAV and CAZ disks but was also
positive with three other screening combinations. None of the
Citrobacter isolates showed tazobactam induction of AmpC.
For Citrobacter species, the rank order of zone reduction was
as follows: IMI/CTX ⬎ IMI/FOX ⬎ IMI/TZP ⬎ IMI/CAZ ⬎
FOX/PIP (Table 1).
Serratia spp. All 13 Serratia species collected for the study
were identified as S. marcescens, and 12 of 13 gave a positive
induction test with one or more of the inducer/substrate combinations. The sensitivity of each combination for the detection
of AmpC induction with S. marcescens was FOX/PIP, 66.7%;
IMI/CTX, 100%; IMI/CAZ, 91.7%; IMI/TZP, 91.7%; and
IMI/FOX, 8.3% (Table 1). AmpC induction by clavulanic acid
was observed in 2 of the 12 isolates by comparing the CAZCLAV and CAZ zone sizes, but both were identified by three
or more of the inducer/substrate combinations. None of the
isolates showed evidence of ESBL or metallo-␤-lactamase production, but one strain appeared to be induced for AmpC
production in the presence of tazobactam. None of the isolates
was stably derepressed for AmpC synthesis, and one could not
be induced with any of the combinations tested. For Serratia
species, the rank order of zone reduction for individual screens
was as follows: IMI/TZP ⬎ IMI/CTX ⬎ FOX/PIP ⬎ IMI/

5947

5948

DUNNE AND HARDIN

dopenicillins (including TZP) for Enterobacter and Serratia
spp. and C. freundii (actual results were retained and made
available by request to infectious diseases and pharmacy personnel). Actual IMI and cefepime results were provided for all
ESCP due to the stability of these agents against AmpC (8, 11),
although IMI is a restricted agent at our institution and requires approval for use. CAZ is tested against all isolates of
P. aeruginosa, but the results are suppressed since this is currently not a formulary drug and requires prior approval.
In light of our results, routine screening of ESCP for AmpC
induction seems fruitless at our institution given that 85% of
isolates are inducible and 11% have stable high-level expression.
One exception might include the testing of Citrobacter spp. other
than C. freundii, where inducible AmpC does not strictly align
with species. Our current practice of reporting susceptibility
results for AmpC-stable ␤-lactam and carbapenem agents
along with other AmpC-independent classes of antibiotics for
ESCP, while providing a default resistant interpretation for
AmpC-labile agents, seems reasonable given these results. One
could argue that TZP is an orphan in this algorithm in that the
combination is a poor inducer of AmpC and is potentially
useful for treatment of infections caused by ESCP (1, 11)
However, TZP proved to be the most sensitive AmpC substrate in the present study when combined with IMI as an
inducer. Although tazobactam has not been previously recognized as an inducer of AmpC activity (1), we observed three
isolates of P. aeruginosa and one of S. marcescens that suggested tazobactam induction of AmpC. These results were
reproduced in repeat trials and are worthy of additional investigation. Indeed, actual TZP results are reported in our algorithm for P. aeruginosa, but its use, like IMI, is restricted and
requires approval.
Despite our attempts to utilize single patient isolates for the
present study, it is likely that many of the strains represent
clonal hospital flora and either over- or underestimate the
performance of the screening assays. Nonetheless, these isolates are representative of the mix and proportion of ESCP
organisms encountered in our facility. Therefore, it would be
reasonable for laboratories considering the use of an AmpC
induction screening assay to assess site-specific performance
characteristics with local flora.
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loss of OprD (D2 porin protein) as previously described (9, 10,
12, 19) and not through acquisition of a metallo-␤-lactamase.
The choice of inducer/substrate combinations evaluated in
the present study was limited to candidates currently part of
our susceptibility panel. Only two inducers were considered
(IMI and FOX) based on previous observations that the
former is a strong inducer but a poor substrate for AmpC
activity, while the latter is both a strong inducer and a labile
substrate (11). Likewise, substrates were selected for known
susceptibility to hydrolysis by AmpC enzymes. One combination (FOX/PIP) was chosen based on a previous study demonstrating 100% sensitivity for the detection of inducible
AmpC among 10 clinical isolates of P. aeruginosa (9). Our
study found poor sensitivity (ⱕ40%) of this combination for
the detection of inducible AmpC in P. aeruginosa, Enterobacter
spp., and Citrobacter spp. and for all ESCP organisms combined. As a substrate, FOX fared less well when combined with
IMI as an inducer where the combination had an overall sensitivity of 2.3% for ESCP. The poor performance of this combination can be explained by the high rate of resistance of
study isolates to FOX. A model substrate for this assay requires a zone of inhibition of ⱖ2 mm on the uninduced side of
the disk to register a positive response on the induced side. In
the case of FOX/IMI, only 23 of 200 test organisms generated
a zone of inhibition of ⬎2 mm on the uninduced side of the
disk, and most had no zone at all. Although the sensitivity of
the IMI/CTX combination was 100% for Serratia species, the
overall sensitivity was only 75.4% for all isolates—a result of
resistance among P. aeruginosa (50 of 134 strains with a zone of
inhibition of ⬍2 mm on the uninduced side of the CTX disk).
We found that the combination of IMI/CAZ or IMI/TZP provided excellent sensitivity (94.2 and 97.1%, respectively) for
the detection of inducible AmpC. The greater sensitivity of the
latter is partially due to background ESBL activity. All five
E. cloacae isolates with ESBL expression had a positive test for
induced AmpC using the IMI/TZP combination and a negative
result with the IMI/CAZ pair. The mean differences in the
inhibitory zone size between the induced and uninduced sides
of the substrate disk for the IMI/CAZ and IMI/TZP combinations were 3.5 and 4.0 mm, respectively, so that either test was
easy to interpret. Regardless of the substrate/inducer combination, the specificity of a positive test was determined to be
100% based on ABP inhibition of AmpC activity.
In can be argued that the selection of an antimicrobial agent
for infections caused by ESCP organisms should be based on
the assumption that certain drugs such as FOX or extendedspectrum cephalosporins might increase the risk of selecting
stably derepressed AmpC-producing strains during therapy
(4, 5, 11, 13). Other agents, such as piperacillin, seem to be less
likely to select for derepressed mutants in vitro but clearly have
reduced activity against strains already derepressed for AmpC
production (11). If a simple screening test for AmpC induction
was available, it would be possible to modify antibiotic reporting cascades so as to avoid utilization of agents for ESCP that
act as substrates of AmpC when dealing with a site of infection
where extremely high levels of antibiotics cannot be assured
(13). Prior to this analysis, the microbiology laboratory in conjunction with the infectious diseases service and pharmacy had
elected to issue a default interpretation of “resistant” for narrow-, extended-, and broad-spectrum cephalosporins and urei-
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